Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of omalizumab in patients with chronic rhinosinusitis with nasal polyps
2017-003450-16Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Roche. Primary endpoint: Incidence of serious and non-serious adverse events. Started Jan 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2017-003450-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003450-16.